850717-64-5

Basic information

• Product Name: PDK1 Inhibitor
• Synonyms: BX-517;BX517(PDK1 inhibitor2);5-Ureido-3-[1-(pyrrol-2-yl)ethylidene]indolin-2-one;PDK1 Inhibitor 2
• CAS NO: 850717-64-5
• Molecular Formula: C15H14N4O2
• Molecular Weight: 282.29726
• Mol File: 850717-64-5.mol

Chemical Properties

• Appearance: /
• Solubility: insoluble in H2O; insoluble in EtOH; ≥8.55 mg/mL in DMSO
• CAS DataBase Reference: PDK1 Inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: PDK1 Inhibitor(850717-64-5)
• EPA Substance Registry System: PDK1 Inhibitor(850717-64-5)

Safety Data

• Hazardous Substances Data: 850717-64-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PDK1 Inhibitor is used as a therapeutic agent for targeting the PDK1 protein, which plays a crucial role in various cellular processes, including cell survival, growth, and metabolism. By inhibiting PDK1, BX-517 can potentially be employed in the treatment of diseases where the PDK1 pathway is dysregulated, such as certain types of cancer.
Additionally, due to its high selectivity and potency, PDK1 Inhibitor can be utilized in research settings to study the role of PDK1 in cellular processes and to develop a better understanding of its implications in disease mechanisms. This can lead to the discovery of new therapeutic targets and the advancement of personalized medicine approaches.

Biological Activity

bx-517 is a potent and selective inhibitor of pdk1 that binds to the atp binding pocketof the protein (ic50 = 6 nm). bx-517 also blocks activation of akt in tumor cells with 10-fold more potent (ic50 = 0.1–1.0 μm) than its analogs tested at the highest dose tested (10 μm). [1] the phosphoinositide-dependent kinase-1 (pdk1) is a ser/thr kinase that is a crucial activator of a range of protein kinases in the agc kinase super-family that play key roles in the progression of cancer and for the activation of akt, s6 kinase, and protein kinase c. [2]

references

1. islam i, brown g, bryant j et al. indolinone based phosphoinositide-dependentkinase-1 (pdk1) inhibitors. part 2: optimization of bx-517. bioorg med chem lett.2007 jul 15;17(14):3819-25. 2. islam i, bryant j, chou yl etc. indolinone based phosphoinositide-dependent kinase-1 (pdk1)inhibitors. part 1: design, synthesis and biological activity. bioorg med chem lett. 2007 jul 15;17(14):3814-8.

Upstream product

• 946843-76-1 C₁₄H₁₃N₃O 
• 1118-02-1 trimethylsilyl isocyanate 
• 946843-72-7 C₁₄H₁₁N₃O₃ 
• 20870-79-5 5-nitrooxindole 
• 1072-83-9 2-Acetylpyrrole 

Relevant articles and documents

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity

HTS screening identified 1 with micromolar inhibitory activity against PDK1. Optimization of 1 afforded 4i (BX-517) which has single-digit nanomolar activity against PDK1 and excellent selectivity against PKA.

Indolinone derivatives and their use in treating disease-states such as cancer

Indolinone derivatives, such as compounds of the formula (I): wherein A, m, n, R1, R2, R3, R5 and R6 are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.